Several lines of evidence suggest that schizophrenia is associated with deficits in
glutamatergic transmission at the N-methyl-d-aspartate (NMDA) receptors. Glycine is a …

Abstract Treatment options for schizophrenia that address all symptom categories (positive,
negative, and cognitive) are lacking. Novel compounds that regulate signaling by the major …

Multiple lines of evidence suggest that an abnormality of glutamatergic neurotransmission
via N-methyl-D-aspartate (NMDA) receptors might be implicated in the pathophysiology of …

Glycinergic neurotransmission has long been known for its role in spinal motor control.
During the last two decades, additional functions have become increasingly recognized …

On the face of it, the treatment of schizophrenia offers lots of choice: there are more than 30
antipsychotic drugs licensed for first-line treatment. However, as they all essentially use the …

Concentrations of extracellular glycine in the central nervous system are regulated by
Na+/Cl−-dependent glycine transporters, GLYT1 and GLYT2. N-Arachidonylglycine (NAGly) …

It is widely accepted that glycine transporters of the GLYT1 type are situated on astrocytes
whereas GLYT2 are present on glycinergic neuronal terminals where they mediate glycine …

The occupation of the glycine binding-site is a prerequisite for NMDA receptor activation by
glutamate. To analyze the regulation of NMDA receptor function by the glycine transporter 1 …

In the central nervous system, glycine is a coagonist with glutamate at the N-methyl-d-
aspartate subtype of ionotropic glutamate receptors. The GLYT1b subtype of glycine …

The potential role of N-methyl-D-aspartate (NMDA)-type glutamate receptors in the
pathogenesis of schizophrenia was first proposed almost 20 years ago on the basis of …